Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics

Leuk Lymphoma. 2002 May;43(5):953-9. doi: 10.1080/10428190290021380.

Abstract

Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA-damaging chemotherapeutics. A second generation construct with an improved recombinant cytotoxic RNAse is described. Targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin-containing immunoconjugates.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Antigens, CD
  • Antigens, Differentiation, B-Lymphocyte
  • Cell Adhesion Molecules*
  • Humans
  • Immunotoxins / therapeutic use*
  • Lectins / antagonists & inhibitors*
  • Lymphoma, B-Cell / drug therapy*
  • Mice
  • Mice, SCID
  • Ribonucleases / therapeutic use*
  • Sialic Acid Binding Ig-like Lectin 2

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation, B-Lymphocyte
  • CD22 protein, human
  • Cd22 protein, mouse
  • Cell Adhesion Molecules
  • Immunotoxins
  • Lectins
  • Sialic Acid Binding Ig-like Lectin 2
  • Ribonucleases
  • rapLR1 enzyme